Andremacon is an innovative SME focused on the study and development of new pharmaceutical approaches in the area of precision oncology and target therapy, with particular attention to brain tumors, neuroinflammatory and degenerative diseases.

Based on the activities carried out so far, Andremacon holds patents and know-how relating to processes/drugs for brain tumors. The company encompasses transversal biotechnological, pharmaceutical, clinical, scientific research and entrepreneurial skills.

Today Andremacon is led by a board of directors with managerial skills consolidated in other successful businesses, which, through an industrial plan with objectives, aim to establish Andremacon in the biotech market.

The scientific team is made up also of the founding members, internationally recognized researchers in various field of translational and clinical research.